The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Paola Queirolo, Dario Palleschi(Presidio Ospedaliero), Andrea Pietro Sponghini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Teresa Troiani(University of Campania "Luigi Vanvitelli"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Fabrizio Carnevale‐Schianca(Candiolo Cancer Institute), Francesca Consoli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Ernesto Rossi(Agostino Gemelli University Polyclinic), Pietro Quaglino(Department of Medical Sciences), Roberta Depenni(University of Modena and Reggio Emilia), Riccardo Marconcini(Azienda Ospedaliera Universitaria Pisana), Alessandro Marco Minisini, Maria Francesca Morelli(Istituto Dermopatico dell'Immacolata), Gaetana Rinaldi(AOL (United States)), Ilaria Marcon(Ospedale di Circolo e Fondazione Macchi), Maria Banzi(Azienda Ospedaliera S.Maria)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k